Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
ZD6126
Другие языки:

    ZD6126

    Подписчиков: 0, рейтинг: 0
    ZD6126
    Skeletal formula
    Ball-and-stick model
    Clinical data
    Other names ANG 453; AZD 6126; N-Acetylcolchicinol dihydrogenphosphate
    Identifiers
    • Phosphoric acid mono-(5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl) ester
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C20H24NO8P
    Molar mass 437.385 g·mol−1
    3D model (JSmol)
    • CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=C1C=C(C=C3)OP(=O)(O)O)OC)OC)OC
    • InChI=1S/C20H24NO8P/c1-11(22)21-16-8-5-12-9-17(26-2)19(27-3)20(28-4)18(12)14-7-6-13(10-15(14)16)29-30(23,24)25/h6-7,9-10,16H,5,8H2,1-4H3,(H,21,22)(H2,23,24,25)/t16-/m0/s1 ☒N
    • Key:UGBMEXLBFDAOGL-INIZCTEOSA-N ☒N
     ☒NcheckY (what is this?)  (verify)

    ZD6126 is a vascular-targeting agent and a prodrug of N-acetylcolchinol, related to colchicine. It has shown promising results on tumors in mice.

    A phase I clinical trial identified gastrointestinal and cardiac effects as limiting dosing. Two phase II clinical trials were suspended investigating ZD6126 in metastatic renal cell carcinoma and metastatic colorectal cancer.

    ZD6126 was being investigated by AstraZeneca as a vascular disrupting agent (VDA). However, the trials were halted, after it became apparent that ZD6126 was too cardiotoxic at the required doses.


    Новое сообщение